JP2016128474A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016128474A5 JP2016128474A5 JP2016013547A JP2016013547A JP2016128474A5 JP 2016128474 A5 JP2016128474 A5 JP 2016128474A5 JP 2016013547 A JP2016013547 A JP 2016013547A JP 2016013547 A JP2016013547 A JP 2016013547A JP 2016128474 A5 JP2016128474 A5 JP 2016128474A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- composition according
- antibody
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 239000012634 fragment Substances 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 238000011275 oncology therapy Methods 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102100034384 Plexin-B1 Human genes 0.000 claims 1
- 101710100559 Plexin-B1 Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 238000009175 antibody therapy Methods 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 210000004969 inflammatory cell Anatomy 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17682609P | 2009-05-08 | 2009-05-08 | |
| US61/176,826 | 2009-05-08 | ||
| US32521310P | 2010-04-16 | 2010-04-16 | |
| US61/325,213 | 2010-04-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012510026A Division JP6059013B2 (ja) | 2009-05-08 | 2010-05-07 | 抗ｃｄ１００抗体およびこれを使用するための方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017026605A Division JP2017113017A (ja) | 2009-05-08 | 2017-02-16 | 抗ｃｄ１００抗体およびこれを使用するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016128474A JP2016128474A (ja) | 2016-07-14 |
| JP2016128474A5 true JP2016128474A5 (cg-RX-API-DMAC7.html) | 2016-12-01 |
| JP6096946B2 JP6096946B2 (ja) | 2017-03-15 |
Family
ID=43050912
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012510026A Active JP6059013B2 (ja) | 2009-05-08 | 2010-05-07 | 抗ｃｄ１００抗体およびこれを使用するための方法 |
| JP2016013547A Active JP6096946B2 (ja) | 2009-05-08 | 2016-01-27 | 抗ｃｄ１００抗体およびこれを使用するための方法 |
| JP2017026605A Pending JP2017113017A (ja) | 2009-05-08 | 2017-02-16 | 抗ｃｄ１００抗体およびこれを使用するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012510026A Active JP6059013B2 (ja) | 2009-05-08 | 2010-05-07 | 抗ｃｄ１００抗体およびこれを使用するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017026605A Pending JP2017113017A (ja) | 2009-05-08 | 2017-02-16 | 抗ｃｄ１００抗体およびこれを使用するための方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (6) | US8496938B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2427212B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6059013B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20170080705A (cg-RX-API-DMAC7.html) |
| CN (2) | CN108912228B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2010245668B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2760890C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2427212T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA025245B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2647823T3 (cg-RX-API-DMAC7.html) |
| IL (3) | IL216002A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2011011718A (cg-RX-API-DMAC7.html) |
| NO (1) | NO2427212T3 (cg-RX-API-DMAC7.html) |
| NZ (2) | NZ618067A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2427212T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2427212T (cg-RX-API-DMAC7.html) |
| SG (1) | SG175417A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010129917A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201108162B (cg-RX-API-DMAC7.html) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8496938B2 (en) | 2009-05-08 | 2013-07-30 | Vaccinex, Inc. | Anti-CD100 neutralizing neutralizing antibodies and methods of using the same |
| EP2487242A1 (en) * | 2011-02-09 | 2012-08-15 | Ruprecht-Karls-Universität Heidelberg | B-type plexin antagonists and uses thereof |
| US9447191B2 (en) | 2011-05-13 | 2016-09-20 | National University Corporation Tokyo Medical And Dental University | Osteogenesis promoter |
| CN104168956A (zh) | 2011-10-11 | 2014-11-26 | 瓦西尼斯公司 | 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途 |
| US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) * | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| US10626163B2 (en) | 2013-01-25 | 2020-04-21 | Brandeis University | Methods of modulating GABAergic inhibitory synapse formation and function |
| CN105229032A (zh) * | 2013-03-18 | 2016-01-06 | 比奥塞罗克斯产品公司 | 人源化抗cd134(ox40)抗体及其应用 |
| NZ631015A (en) * | 2013-06-25 | 2019-08-30 | Vaccinex Inc | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
| NZ630881A (en) * | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| PT3445397T (pt) | 2016-04-22 | 2023-01-13 | Vaccinex Inc | Exibição de proteína integral de membrana sobre viriões envelopados extracelulares de poxvírus |
| EP3494131B1 (en) | 2016-08-02 | 2024-09-18 | Vaccinex, Inc. | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| ES2912269T3 (es) | 2016-09-27 | 2022-05-25 | Cero Therapeutics Inc | Moléculas de receptor de engullimiento quimérico |
| FI3600419T3 (fi) | 2017-03-20 | 2023-11-08 | Vaccinex Inc | Syövän hoitaminen semaforiini-4d-vasta-aineella yhdistelmänä epigeneettistä järjestelmää moduloivan aineen kanssa |
| US11274146B2 (en) * | 2017-03-23 | 2022-03-15 | The Trustees Of The University Of Pennsylvania | Anti-C5a antibodies and uses thereof |
| WO2018204895A1 (en) | 2017-05-05 | 2018-11-08 | Vaccinex, Inc. | Human anti-semaphorin 4d antibody |
| MX2020007266A (es) | 2017-09-26 | 2020-09-07 | Cero Therapeutics Inc | Moleculas del receptor quimerico de engullido y metodos de uso. |
| US12303551B2 (en) | 2018-03-28 | 2025-05-20 | Cero Therapeutics Holdings, Inc. | Cellular immunotherapy compositions and uses thereof |
| US12291557B2 (en) | 2018-03-28 | 2025-05-06 | Cero Therapeutics Holdings, Inc. | Chimeric TIM4 receptors and uses thereof |
| EP3774864A1 (en) | 2018-03-28 | 2021-02-17 | Cero Therapeutics, Inc. | Chimeric engulfment receptors and uses thereof for neurodegenerative diseases |
| CN110713537B (zh) * | 2018-07-13 | 2023-04-21 | 江苏怀瑜药业有限公司 | 一种sema4d抗体及其制备方法和应用 |
| CN109125731B (zh) * | 2018-10-22 | 2019-10-25 | 华中科技大学同济医学院附属协和医院 | Sema4D/PlexinB1抑制剂在制备治疗及预防眼底血管疾病药物中的应用 |
| JP7362767B2 (ja) * | 2019-03-28 | 2023-10-17 | バクシネックス インコーポレーティッド | がん療法で使用するためのセマフォリン－４ｄアンタゴニスト |
| US11660330B2 (en) | 2019-06-21 | 2023-05-30 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy |
| WO2021013061A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 一种人源化抗vegfr2抗体及其应用 |
| AU2020322474A1 (en) | 2019-08-01 | 2022-03-10 | Vaccinex,Inc. | Combined inhibition of semaphorin-4D and TGFβ and compositions therefor |
| AU2021297152A1 (en) | 2020-06-25 | 2023-02-02 | The Sydney Children's Hospitals Network | Use of semaphorin-4D binding molecules for the treatment of Rett syndrome |
| CN113583122B (zh) * | 2021-07-29 | 2023-08-29 | 武汉华美生物工程有限公司 | 抗人sema4d抗体及其制备方法和应用 |
| KR20240063995A (ko) | 2021-09-27 | 2024-05-10 | 백시넥스 인코포레이티드 | 신경퇴행성 장애를 치료하기 위한 항-세마포린-4d 결합 분자의 사용을 위한 예측 결과 프로파일링 |
| KR20240131324A (ko) * | 2021-11-03 | 2024-08-30 | 럿거스, 더 스테이트 유니버시티 오브 뉴 저지 | 수용체 티로신 키나제 EphA5에 대한 항체-약물 접합체 |
| US20230331863A1 (en) | 2022-02-13 | 2023-10-19 | Vaccinex, Inc. | Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease |
| CN117866091A (zh) * | 2022-10-12 | 2024-04-12 | 三优生物医药(上海)有限公司 | 抗cd100抗体及其用途 |
| CN118108841A (zh) * | 2022-11-30 | 2024-05-31 | 三优生物医药(上海)有限公司 | 抗cd100抗体及其用途 |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5070192A (en) | 1988-03-23 | 1991-12-03 | The Johns Hopkins University | Cloned human topoisomerase i: cdna expression, and use for autoantibody detection |
| DE68921982D1 (de) | 1988-06-14 | 1995-05-04 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| EP0521985B1 (en) | 1990-03-20 | 1997-09-24 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
| WO1992005793A1 (en) | 1990-10-05 | 1992-04-16 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
| EP0557300B1 (en) | 1990-10-29 | 1997-11-19 | Chiron Corporation | Bispecific antibodies, method of production, and uses thereof |
| EP0574395B1 (en) | 1990-11-09 | 2002-06-12 | GILLIES, Stephen D. | Cytokine immunoconjugates |
| ES2093778T3 (es) | 1991-04-26 | 1997-01-01 | Surface Active Ltd | Nuevos anticuerpos y metodos para su uso. |
| US6497872B1 (en) | 1991-07-08 | 2002-12-24 | Neurospheres Holdings Ltd. | Neural transplantation using proliferated multipotent neural stem cells and their progeny |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| WO1993017715A1 (en) | 1992-03-05 | 1993-09-16 | Board Of Regents, The University Of Texas System | Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells |
| AU671608B2 (en) * | 1993-01-14 | 1996-09-05 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Recombinant anti-HIV antibody and preparation thereof |
| US5639856A (en) | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| ATE293640T1 (de) | 1997-04-07 | 2005-05-15 | Genentech Inc | Anti-vegf antikörper |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| JP2001516226A (ja) | 1997-04-11 | 2001-09-25 | デンドレオン コーポレイション | 腫瘍関連性の抗原に対する免疫応答を誘導するための組成物および方法 |
| EP0892047A3 (de) | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
| US5968829A (en) | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
| US6638501B1 (en) | 1997-09-29 | 2003-10-28 | Neurospheres Holdings Ltd. | Use of multipotent neural stem cell progeny to augment non-neural tissues |
| US5958767A (en) | 1998-08-14 | 1999-09-28 | The Children's Medical Center Corp. | Engraftable human neural stem cells |
| JP4451987B2 (ja) | 1998-11-10 | 2010-04-14 | ユニバーシティー オブ ロチェスター | 標的抗原に特異的なｔ細胞ならびにこれに基づく方法およびワクチン |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| JP3787473B2 (ja) | 1999-11-30 | 2006-06-21 | 独立行政法人科学技術振興機構 | セマフォリン受容体 |
| US6635742B1 (en) | 2000-01-25 | 2003-10-21 | Nuvelo, Inc. | Antibodies specific for semaphorin-like polypeptides |
| US7468277B2 (en) | 1999-12-23 | 2008-12-23 | Cornell Research Foundation, Inc. | Enriched preparation of human fetal multipotential neural stem cells |
| CN1329060A (zh) * | 2000-06-19 | 2002-01-02 | 上海博德基因开发有限公司 | 一种新的多肽——人semaphorin蛋白9和编码这种多肽的多核苷酸 |
| WO2002102855A2 (en) | 2000-11-17 | 2002-12-27 | University Of Rochester | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
| US7319139B2 (en) | 2001-01-29 | 2008-01-15 | Biogen Idec, Inc. | TAG-72 specific CH2 domain deleted antibodies |
| AU2002314495A1 (en) * | 2001-06-20 | 2003-01-02 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| US20030020733A1 (en) | 2001-07-24 | 2003-01-30 | Yin Memphis Zhihong | Computer display having selective area magnification |
| ITTO20010128U1 (it) | 2001-07-25 | 2003-01-25 | Aris Spa | Struttura ausiliaria particolarmente per l'incremento della capacita'di trasporto dei veicoli cingolati polivalenti tipo m 113 e derivati. |
| US6905856B2 (en) * | 2001-12-21 | 2005-06-14 | Genzyme Glycobiology Research Institute, Inc. | Soluble GlcNAc phosphotransferase |
| US20080219974A1 (en) * | 2002-03-01 | 2008-09-11 | Bernett Matthew J | Optimized antibodies that target hm1.24 |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| EP1365018A1 (en) | 2002-05-23 | 2003-11-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | CD100 semaphorin in myelination |
| JP4524181B2 (ja) * | 2002-05-30 | 2010-08-11 | マクロジェニクス，インコーポレーテッド | Ｃｄ１６ａ結合タンパク質および免疫障害治療のための使用 |
| US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
| EP1442749A1 (en) * | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| RS20160203A1 (sr) | 2003-05-30 | 2016-10-31 | Genentech Inc | Tretman sa anti-vegf antitelima |
| AU2004272607B2 (en) * | 2003-09-11 | 2008-11-06 | Cornerstone Therapeutics Inc. | Monoclonal antibodies against HMGB1 |
| WO2005055936A2 (en) | 2003-12-04 | 2005-06-23 | Vaccinex, Inc. | Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |
| JP2008507252A (ja) | 2003-12-11 | 2008-03-13 | ジェネンテック・インコーポレーテッド | Ｃ−ｍｅｔ二量体化及び活性化を阻害するための方法と組成物 |
| CN102942631B (zh) | 2004-08-05 | 2015-03-25 | 健泰科生物技术公司 | 人源化抗c-met拮抗剂 |
| US20060147449A1 (en) | 2004-11-15 | 2006-07-06 | Brass Lawrence F | Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses |
| JP2008535856A (ja) * | 2005-04-07 | 2008-09-04 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | 癌の診断、検出および治療におけるｓｅｍａ４ｄ |
| EP2299267A3 (en) * | 2005-11-16 | 2011-05-04 | Novartis AG | Biomarkers for anti-NogoA antibody treatment in spinal cord injury |
| JP2007308465A (ja) | 2006-05-15 | 2007-11-29 | Boehringer Ingelheim Internatl Gmbh | 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法 |
| US7657639B2 (en) * | 2006-07-21 | 2010-02-02 | International Business Machines Corporation | Method and system for identity provider migration using federated single-sign-on operation |
| WO2008025020A2 (en) * | 2006-08-25 | 2008-02-28 | Seattle Genetics, Inc. | Cd30 binding agents and uses thereof |
| US9382327B2 (en) | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
| ATE494306T1 (de) | 2007-02-14 | 2011-01-15 | Vaccinex Inc | Humanisierte anti-cd100-antikörper |
| CA2678618C (en) | 2007-02-21 | 2019-03-12 | Vaccinex, Inc. | Modulation of nkt cell activity with antigen-loaded cd1d molecules |
| JP5690593B2 (ja) | 2007-12-26 | 2015-03-25 | ヴァクシネックス， インコーポレイテッド | 抗ｃ３５抗体併用療法および方法 |
| AR070134A1 (es) | 2008-01-10 | 2010-03-17 | Genentech Inc | Agonistas de plexind1 que comprende un fragmento de semaforina 3e(sema3e) y su uso |
| US8496938B2 (en) | 2009-05-08 | 2013-07-30 | Vaccinex, Inc. | Anti-CD100 neutralizing neutralizing antibodies and methods of using the same |
| EP2429585B1 (en) | 2009-05-15 | 2018-04-18 | IRX Therapeutics, Inc. | Vaccine immunotherapy |
| US8834883B2 (en) | 2010-06-14 | 2014-09-16 | Vaccinex, Inc. | Anti-VEGF antibodies and uses thereof |
| EP2611832B1 (en) | 2010-09-02 | 2017-11-29 | Vaccinex, Inc. | Anti-cxcl13 antibodies and methods of using the same |
| US9447191B2 (en) | 2011-05-13 | 2016-09-20 | National University Corporation Tokyo Medical And Dental University | Osteogenesis promoter |
| HK1201275A1 (en) | 2011-10-06 | 2015-08-28 | Board Of Regents, The University Of Texas System | Anti-human sema4a antibodies useful to treat disease |
| CN104168956A (zh) | 2011-10-11 | 2014-11-26 | 瓦西尼斯公司 | 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途 |
| US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
| CN104520323B (zh) | 2012-03-02 | 2018-05-04 | 瓦西尼斯公司 | 用于治疗b细胞介导的炎性疾病的方法 |
| US9375282B2 (en) | 2012-03-26 | 2016-06-28 | Covidien Lp | Light energy sealing, cutting and sensing surgical device |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| JP6363623B2 (ja) | 2013-01-31 | 2018-07-25 | ヴァクシネックス， インコーポレイテッド | 免疫グロブリンａのレベルを増大するための方法 |
| US9371352B2 (en) | 2013-02-08 | 2016-06-21 | Vaccinex, Inc. | Modified glycolipids and methods of making and using the same |
| NZ631015A (en) | 2013-06-25 | 2019-08-30 | Vaccinex Inc | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| PT3445397T (pt) | 2016-04-22 | 2023-01-13 | Vaccinex Inc | Exibição de proteína integral de membrana sobre viriões envelopados extracelulares de poxvírus |
| EP3494131B1 (en) | 2016-08-02 | 2024-09-18 | Vaccinex, Inc. | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| MX2019009986A (es) | 2017-02-22 | 2019-10-14 | Vaccinex Inc | Deteccion temprana de la activacion de celulas gliales en enfermedades neurodegenerativas o neuroinflamatorias. |
-
2010
- 2010-05-07 US US12/776,187 patent/US8496938B2/en active Active
- 2010-05-07 EP EP10772913.9A patent/EP2427212B1/en active Active
- 2010-05-07 KR KR1020177017649A patent/KR20170080705A/ko not_active Ceased
- 2010-05-07 CN CN201810367413.1A patent/CN108912228B/zh active Active
- 2010-05-07 PT PT107729139T patent/PT2427212T/pt unknown
- 2010-05-07 MX MX2011011718A patent/MX2011011718A/es active IP Right Grant
- 2010-05-07 NZ NZ618067A patent/NZ618067A/en unknown
- 2010-05-07 SG SG2011080025A patent/SG175417A1/en unknown
- 2010-05-07 NO NO10772913A patent/NO2427212T3/no unknown
- 2010-05-07 ES ES10772913.9T patent/ES2647823T3/es active Active
- 2010-05-07 PL PL10772913T patent/PL2427212T3/pl unknown
- 2010-05-07 WO PCT/US2010/034116 patent/WO2010129917A2/en not_active Ceased
- 2010-05-07 NZ NZ596136A patent/NZ596136A/en active IP Right Revival
- 2010-05-07 MX MX2014010424A patent/MX353352B/es unknown
- 2010-05-07 EP EP17186852.4A patent/EP3320920A1/en not_active Withdrawn
- 2010-05-07 AU AU2010245668A patent/AU2010245668B2/en active Active
- 2010-05-07 CA CA2760890A patent/CA2760890C/en active Active
- 2010-05-07 CN CN201080029914.0A patent/CN102458468B/zh active Active
- 2010-05-07 KR KR1020117029324A patent/KR101754433B1/ko active Active
- 2010-05-07 EA EA201171374A patent/EA025245B1/ru unknown
- 2010-05-07 JP JP2012510026A patent/JP6059013B2/ja active Active
- 2010-05-07 DK DK10772913.9T patent/DK2427212T3/en active
-
2011
- 2011-10-27 IL IL216002A patent/IL216002A/en active IP Right Grant
- 2011-11-07 ZA ZA2011/08162A patent/ZA201108162B/en unknown
-
2012
- 2012-06-14 US US13/517,807 patent/US8816058B2/en active Active
-
2013
- 2013-03-12 US US13/797,048 patent/US9605055B2/en active Active
- 2013-03-13 US US13/800,713 patent/US9676840B2/en active Active
-
2016
- 2016-01-27 JP JP2016013547A patent/JP6096946B2/ja active Active
- 2016-02-21 IL IL244197A patent/IL244197A0/en active IP Right Grant
- 2016-10-18 AU AU2016247068A patent/AU2016247068A1/en not_active Abandoned
-
2017
- 2017-02-16 JP JP2017026605A patent/JP2017113017A/ja active Pending
- 2017-04-28 US US15/581,573 patent/US11274149B2/en active Active
-
2018
- 2018-08-23 IL IL261348A patent/IL261348A/en unknown
-
2022
- 2022-01-31 US US17/588,427 patent/US12006364B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016128474A5 (cg-RX-API-DMAC7.html) | ||
| TWI822760B (zh) | 結合ｃｄ４７蛋白的融合蛋白及其應用 | |
| JP2015529641A5 (cg-RX-API-DMAC7.html) | ||
| EP3250586B1 (en) | Novel proteins specific for angiogenesis | |
| US12378295B2 (en) | Rationally designed protein compositions | |
| JP2021524278A (ja) | 抗メソテリン抗体 | |
| CN108026169A (zh) | 抗人cd137的完全人抗体及其应用 | |
| JP2019520591A5 (cg-RX-API-DMAC7.html) | ||
| JP2013539369A5 (cg-RX-API-DMAC7.html) | ||
| JP2015525208A5 (cg-RX-API-DMAC7.html) | ||
| NZ713461A (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer | |
| CN108473575A (zh) | 抗-bcma多肽和蛋白质 | |
| WO2014012007A4 (en) | Rspo3 binding agents and uses thereof | |
| RU2016101711A (ru) | Высокостабильный т-клеточный рецептор и способ его получения и применения | |
| PE20180249A1 (es) | Anticuerpos neutralizadores anti-ccl20 | |
| RU2012139829A (ru) | АНТИТЕЛА, НЕЙТРАЛИЗУЮЩИЕ ИНТЕГРИН ανβ8 | |
| CN108409860A (zh) | 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用 | |
| US10703810B2 (en) | Fusion polypeptides which bind vascular endothelial growth factor a (VEGF-A) and angiopoietin-2 (Ang-2) | |
| JP2020530770A5 (cg-RX-API-DMAC7.html) | ||
| HRP20180917T1 (hr) | Novi fragmenti protutijela, pripravci i njihova upotreba | |
| WO2022089644A1 (zh) | 靶向cd5的全人源抗体、全人源嵌合抗原受体(car)及其应用 | |
| KR20180030552A (ko) | 개질된 자가-에피토프에 대한 항종양 면역 반응 | |
| WO2018175310A4 (en) | Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy | |
| JP2020511541A5 (cg-RX-API-DMAC7.html) | ||
| KR20230147675A (ko) | 다중 도메인 융합 단백질 및 이의 응용 |